Background: Radium-223 dichloride (radium-223) is approved for patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases, and no visceral disease using a dosing regimen of 6 injections (55 kBq/kg intravenously; 1 injection every 4 weeks). Early results from international, open-label, phase 1/2 study NCT01934790 showed that re-treatment with radium-223 was well tolerated with favorable effects on disease progression. Here we report safety and efficacy findings from 2-year follow-up of the radium-223 re-treatment study.
hematologic parameters were adequate and chemotherapy had not been administered after the initial course of radium-223. Concomitant cytotoxic agents were not allowed during re-treatment but were allowed at the investigator's discretion during follow-up; other concomitant agents for prostate cancer (including abiraterone acetate or enzalutamide) were allowed at investigator's discretion. The primary objective was safety. Exploratory objectives included time to radiographic bone progression, radiographic progression-free survival (rPFS), time to total alkaline phosphatase (tALP), and prostate-specific antigen (PSA) progression, overall survival (OS), time to first symptomatic skeletal event (SSE), and SSE-free survival, all calculated from re-treatment start. Evaluation of safety and exploratory efficacy objectives included active 2-year follow-up. Safety results from active follow-up and updated efficacy are reported.
Results: Overall, 44 patients were re-treated with radium-223; 29 (66%) completed all 6 injections, and 34 (77%) entered 2-year active follow-up, during which no new safety concerns and no serious drug-related adverse events were noted. rPFS events (progression or death) occurred in 19 (43%) of 44 patients; median rPFS was 9.9 months. Radiographic bone progression occurred in 5 (11%) of 44 patients.
Median OS was 24.4 months. Median times to first SSE and SSE-free survival were 16.7 and 12.8 months, respectively. Median time to tALP progression was not reached; median time to PSA progression was 2.2 months.
Conclusions: Re-treatment with radium-223 in this selected patient population was well tolerated, led to minimal hematologic toxicity, and provided continued disease control in bone at 2-year follow-up.
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alkaline phosphatase, prostate-specific antigen, safety, SSEs, survival, symptomatic skeletal events 1 | INTRODUCTION Radium-223 dichloride (radium-223) is the first targeted alpha therapy approved for patients with metastatic castration-resistant prostate cancer (mCRPC). In the pivotal phase 3 ALSYMPCA trial, radium-223 plus best standard of care significantly prolonged overall survival (OS) (hazard ratio, 0.70; 95% confidence interval [CI] = 0.58-0.83; P < .001) and delayed time to first symptomatic skeletal event (SSE) (hazard ratio, 0.66; 95% CI = 0.52-0.83; P < .001) versus placebo plus best standard of care in patients with mCRPC. 1,2 Radium-223-treated patients also reported significant benefits in quality of life (QOL), with more patients experiencing meaningful QOL improvement (P = .020) and slower QOL decline over time (P = .006) compared with placebo. 1, 3 Radium-223 was well tolerated with a low incidence of myelosuppression. 1, 4 Based on these results, radium-223 was approved for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases, and no known visceral disease using a dosing regimen of 6 injections (55 kBq/kg intravenously [IV]; 1 injection every 4 weeks). 5, 6 In ALSYMPCA, radium-223 treatment was associated with declines in total alkaline phosphatase (tALP) levels that correlated with increased OS. 7 After completion of the 6-injection regimen, tALP levels began to rise (median time to tALP increase: 7.4 months, radium-223, vs 3.8 months, placebo), and despite initial success, disease progression in bone eventually occurred. 1, 7 The favorable safety profile and low myelosuppression rates observed with radium-223 suggested the possibility that patients who tolerate and benefit from initial radium-223 treatment may also tolerate and further benefit from a rechallenge with up to 6 new radium-223 injections.
An international open-label phase 1/2 study (NCT01934790) was conducted to assess the safety of re-treatment with up to 6 radium-223 injections, administered at 4-week intervals, to patients with mCRPC who previously received and tolerated a full course (6 injections) of radium-223. Early results showed that re-treating patients with up to 6 additional radium-223 injections was well tolerated with favorable effects on disease progression. 8 Among 44 patients, 1 (2%) had radiographic bone progression and 8 (18%) had radiographic soft tissue progression (3 in lymph nodes and 5 in viscera). Median radiographic progression-free survival (rPFS) was 9.9 months, and median time to prostate-specific antigen (PSA) progression was 2.2 months. Median time to tALP progression, median OS, time to first SSE, and SSE-free survival were not reached.
Overall, 3 (7%) of 44 patients experienced grade 3 hematologic treatment-emergent adverse events (TEAEs) (2 anemia, 1 thrombocytopenia); there were no cases of grade 4 hematologic TEAEs. 8 Here we present the extended safety and efficacy results from a 2-year follow-up of this study evaluating radium-223 re-treatment in patients with mCRPC.
| MATERIALS AND METHODS

| Patients
Eligibility criteria for the phase 1/2 radium-223 re-treatment study have been described in detail. 8 Eastern Cooperative Oncology Group performance status (ECOG PS) less than or equal to 2; life expectancy greater than or equal to 6 months; and adequate hematologic, liver, and kidney function.
Patients were excluded if they had visceral metastases greater than or equal to 1 cm in diameter measured less than or equal to 30 days from treatment start or radium-223-related serious or grade 3 or 4 adverse events (AEs) that did not resolve or led to treatment discontinuation. Patients must not have received chemotherapy after their initial course of radium-223. Concomitant abiraterone or enzalutamide was permitted; concomitant chemotherapy was not permitted during the treatment period. Other agents, including denosumab and zoledronic acid, were permitted at the investigator's discretion. All patients provided written informed consent. During active follow-up, systemic anticancer therapies were permitted at the investigator's discretion. 
| Study design and treatment
| Endpoints
The primary endpoint was safety. During the active follow-up period, AEs and serious AEs were recorded if considered to be related to the study medication or if related to an SSE, and all occurrences of leukemia, myelodysplastic syndrome, aplastic anemia, myelofibrosis, primary bone cancer, or any other new primary malignancy were recorded.
Exploratory time-to-event endpoints included rPFS defined as the time from treatment start to radiographic progression or death by any cause, time to radiographic bone progression, time to tALP progression defined as greater than or equal to 25% increase above the nadir value to at least 1.5 × upper limit of normal, time to PSA progression defined as greater than or equal to 25% increase above nadir and an increase in absolute value greater than or equal to 2 ng/ mL above nadir, OS, time to first SSE, and SSE-free survival defined as time from treatment start to first SSE or death. SSEs included external beam radiotherapy (EBRT) to relieve skeletal pain, new symptomatic pathologic bone fractures, spinal cord compression, and tumor-related orthopedic surgical intervention. Time-to-event exploratory efficacy endpoints were calculated from the day of first F I G U R E 1 Radium-223 re-treatment study design. a Exploratory endpoints were calculated from start of radium-223 re-treatment. CRPC, castration-resistant prostate cancer; inj, injection; mets, metastases; OS, overall survival; PSA, prostate-specific antigen; SSE, symptomatic skeletal event; tALP, total alkaline phosphatase [Color figure can be viewed at wileyonlinelibrary.com] radium-223 injection (day 1) to the end of the 2-year follow-up period.
| Assessments
Assessments conducted during treatment were described in the initial report. 8 Assessments during active follow-up were vital signs, physical condition, complete blood counts, blood chemistries including tALP and PSA, ECOG PS, and SSE evaluations every 4 weeks for 12 weeks and then every 12 weeks until 2 years after the last dose of radium-223 was received. Radiographic progression was evaluated by magnetic resonance imaging, or computed tomography of the abdomen and pelvis, chest x-ray, and whole-body technetium-99 bone scans every 12 weeks until disease progression, start of a new anticancer treatment, or as needed to confirm suspected lesions. If progression was detected by bone scan, a confirmatory bone scan was required greater than or equal to 6 weeks later per PCWG2 criteria to confirm radiographic bone progression.
| Statistics
The treatment period began with the first patient first visit (FPFV) on The median time to first SSE was 16.7 months ( Figure 4D) patients. The exploratory efficacy findings suggest a potential benefit from re-treatment, and further evaluation in a larger prospective study is warranted.
| Exploratory efficacy
Patients in the re-treatment study were a very select group and included patients who already had benefited from prior radium-223 therapy. Most patients in the re-treatment study had received and failed prior treatment, including docetaxel (45%), abiraterone (61%), and enzalutamide (30%); however, the survival was better than might be expected. Whether this was due to patient selection or radium-223 treatment cannot be ascertained using this study design.
While direct comparisons between the re-treatment study and ALSYMPCA are not possible, it is noteworthy that efficacy assessments after re-treatment closely paralleled those from initial radium-223 treatment in ALSYMPCA. 1 Median OS was 24.4 months in retreatment compared with 14.9 months in ALSYMPCA; median time to first SSE was 16.7 months with re-treatment versus 15.6 months in ALSYMPCA; and median SSE-free survival was 12.8 months with re-treatment compared with 9.0 months with radium-223 in ALSYMPCA. It must be emphasized that patients in the re-treatment study were a very select group, not only because they had successfully received a full course of 6 radium-223 injections without progression or safety concerns, but also because they had not received chemotherapy after their initial course of radium-223 and their disease had not progressed outside the bone, which improved their prognosis even though they had received multiple lines of treatment. These patients therefore represent a population very different from patients enrolled in ALSYMPCA. Additionally, chemotherapy, radiotherapy, and/or immunotherapy administered during follow-up may have affected the study results, although most of the efficacy endpoints had been reached before the follow-up period.
These results are promising and provide a rationale for further study to more precisely define benefits of re-treatment with radium-223.
Limitations of the study focus on the design (nonrandomized), and the fact that patients were selected for non-bone progression during their first course of radium-223 and for their continued good performance status and good hematologic parameters at baseline before the repeat course of radium-223. Outcomes for a control population with similar parameters are not available. DNA repair alterations were not assessed in this study in a systematic manner, but such studies could be informative with regard to understanding those individuals having more favorable responses to radium-223.
Patients with DNA-repair defects have tumors that may be more susceptible to DNA-damaging agents, such as radium-223 or platinum-based chemotherapy. [9] [10] [11] [12] 5 | CONCLUSIONS Selected patients with CRPC and bone metastases who tolerated and benefited from an initial radium-223 treatment regimen, and whose disease subsequently progressed, appear to benefit from re-treatment with radium-223 at the same dose and schedule. After 2-year follow-up, re-treatment with radium-223 showed minimal hematologic toxicity and sustained benefit in terms of OS and low rates of bone progression; no cumulative or unexpected toxicity was reported. A larger prospective study is needed to further evaluate the efficacy and safety of re-treatment with radium-223; however, based on these results, radium-223 re-treatment for patients who would have been eligible for this trial is feasible. 
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